SCHEDULE: Vanguard Group Reports Zero Alnylam Stake Post-Realignment

The Vanguard Group has reported zero beneficial ownership in Alnylam Pharmaceuticals Inc. common stock following an internal realignment on January 12, 2026.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 10 to Schedule 13G for Alnylam Pharmaceuticals Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0.00 shares, representing 0% of the class of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily a procedural update regarding The Vanguard Group's internal reporting structure rather than a change in investment sentiment towards Alnylam Pharmaceuticals.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how large institutional investors like Vanguard report their holdings, rather than a strategic investment decision regarding Alnylam Pharmaceuticals. Such internal realignments are common for large asset managers to optimize reporting structures or align with internal operational changes, and typically do not signal a change in investment thesis for the underlying company.

Stakeholder Impact

• Shareholders (Alnylam): Minimal direct impact, as the change reflects a reporting adjustment by a large institutional investor, not a fundamental shift in Alnylam's value.
• The Vanguard Group (investors): The change clarifies which Vanguard entities hold specific beneficial ownership, potentially improving transparency for certain investors tracking specific funds.

Key Dates

Keywords

Alnylam Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management